Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prognostic significance of MYC/BCL2 double expression in DLBCL in the genetic classification era.

Cancer science - 1 Jan 2025

Wu Yi-Fan, Yuan Qun-Hui, Shen Hao-Rui, Du Kai-Xin, Shang Chun-Yu, Li Yue, Zhang Xin-Yu, Wu Jia-Zhu, Gao Rui, Wang Li, Li Jian-Yong, Yin Hua, Liang Jin-Hua, Xu Wei

Abstract excerpt

Double expression (DE) is a World Health Organization-recognized adverse prognostic factor in diffuse large B-cell lymphoma (DLBCL). However, the prognostic value of DE in the genetic subtyping era and potential mechanisms remain to be explored. We enrolled 246 DLBCL patients diagnosed between December 2021 and September 2023 in a Jiangsu Province Hospital cohort and included 930 DLBCL patients from three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prognosis

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins c-bcl-2

Share to Proto-Oncogene Proteins c-myc

Source

Open in PubMed Open full text

Identifiers

PMID: 39492801
DOI: 10.1111/cas.16377
PMCID: PMC11711038

Genes

BCL2
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prognostic significance of MYC/BCL2 double expression in DLBCL in the genetic classification era.PMID 39492801Read ↗

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphomaSemantic proximity Read ↗

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphomaSemantic proximity Read ↗

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.Semantic proximity Read ↗

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.Semantic proximity Read ↗

Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosisSemantic proximity Read ↗

High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics.Semantic proximity Read ↗

Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP.Semantic proximity Read ↗

Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?Semantic proximity Read ↗

Prognostic Analysis of Diffuse Large B-Cell Lymphoma Patients Based on Clinical Characteristics, TP53 Mutation Status, and Number of Co-mutated GenesSemantic proximity Read ↗

Biological heterogeneity in diffuse large B-cell lymphomaSemantic proximity Read ↗

TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosisSemantic proximity Read ↗

Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.